Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Folate-Targeted Nanostructured Lipid Carriers (NLCs) Enhance (Letrozol) Efficacy in MCF-7 Breast Cancer Cells

  • Sabzichi, Mehdi (Drug Applied Research Center, Tabriz University of Medical Sciences) ;
  • Mohammadian, Jamal (Research Center for Pharmaceutical Nanotechnology, Tabriz University of Medical Sciences) ;
  • Khosroushahi, Ahmad Yari (Drug Applied Research Center, Tabriz University of Medical Sciences) ;
  • Bazzaz, Roya (Biotechnology Research Center, Tabriz University of Medical Sciences) ;
  • Hamishehkar, Hamed (Drug Applied Research Center, Tabriz University of Medical Sciences)
  • Published : 2016.12.01
⟨ Previous Next ⟩

Abstract

Objective: Targeted-drug-delivery based lipid nanoparticles has emerged as a new and effective approach in cancer chemotherapy. Here, we investigated the ability of folate-modified nanostructured lipid carriers (NLCs) to enhance letrozol (LTZ) efficacy in MCF-7 breast cancer cells. Methods: New formulations were evaluated regarding to particle size and scanning electron microscope (SEM) features. Anti-proliferative effects of LTZ loaded nanoparticles were examined by MTT assay. To understand molecular mechanisms of apoptosis and cell cycle progression, flow cytometric assays were applied. Results: Optimum size of nanoparticles was obtained in mean average of $98{\pm}7nm$ with a poly dispersity index (PDI) of 0.165. The IC50 value was achieved for LTZ was $2.2{\pm}0.2{\mu}M$. Folate-NLC-LTZ increased the percentage of apoptotic cells from 24.6% to 42.2% compared LTZ alone (p<0.05). Furthermore, LTZ loaded folate targeted NLCs caused marked accumulation of cells in the subG1 phase. Conclusion: Taken together, our results concluded that folate targeted LTZ can be considered as potential delivery system which may overcome limitations of clinical application of LTZ and improve drug efficacy in tumor tissue.

Keywords

Acknowledgement

Supported by : Tabriz University of Medical Sciences

References

  1. Amiri B, Ebrahimi-Far M, Saffari Z, et al (2016). Preparation, characterization and cytotoxicity of silibinin-containing nanoniosomes in T47D human breast carcinoma cells. Asian Pac J Cancer Prev, 17, 3833-6.
  2. Amirijavid S, Entezari M, Movafagh A, et al (2015). Cytotoxicity effects of mouse IgG produced against three nanoliposomal human DR5 receptor epitopes on breast cancer cells. Asian Pac J Cancer Prev, 17, 257-61.
  3. Awotwe-Otoo D, Zidan AS, Rahman Z, et al (2012). Evaluation of anticancer drug-loaded nanoparticle characteristics by nondestructive methodologies. AAPS Pharm Sci Tech, 13, 611-22. https://doi.org/10.1208/s12249-012-9782-7
  4. Bartucci M, Dattilo R, Moriconi C, et al (2015). TAZ is required for metastatic activity and chemoresistance of breast cancer stem cells. Oncogene, 34, 681-90. https://doi.org/10.1038/onc.2014.5
  5. Beloqui A, Solinis MA, Rodriguez-Gascon A, et al (2016). Nanostructured lipid carriers: Promising drug delivery systems for future clinics. Nanomedicine: NBM, 12, 143-61. https://doi.org/10.1016/j.nano.2015.09.004
  6. Fujii S, Okinaga T, Ariyoshi W, et al (2013). Mechanisms of G1 cell cycle arrest and apoptosis in myeloma cells induced by hybrid-compound histone deacetylase inhibitor. Biochem Biophys Res Commun, 434, 413-20. https://doi.org/10.1016/j.bbrc.2013.03.043
  7. Ghanbarzadeh S, Khorrami A, Arami S (2014). Preparation of optimized Naproxen nano liposomes using response surface methodology. J Pharm Investig, 44, 33-9. https://doi.org/10.1007/s40005-013-0098-8
  8. Han Y, Li Y, Zhang P, et al (2016). Nanostructured lipid carriers as novel drug delivery system for lung cancer gene therapy. Pharm Dev Technol, 21, 277-81. https://doi.org/10.3109/10837450.2014.996900
  9. Jiang H, Pei L, Liu N, et al (2016). Etoposide-loaded nanostructured lipid carriers for gastric cancer therapy. Drug Deliv, 23, 1379-82.
  10. Kazemi S, Sarabi AA, Abdouss M (2016). Synthesis and characterization of magnetic molecularly imprinted polymer nanoparticles for controlled release of letrozole. Korean J Chem Eng, 33, 3289-97. https://doi.org/10.1007/s11814-016-0171-x
  11. Kuchuk I, Bouganim N, Beusterien K, et al (2013). Preference weights for chemotherapy side effects from the perspective of women with breast cancer. Breast Cancer Res Treat, 142, 101-7. https://doi.org/10.1007/s10549-013-2727-3
  12. Liu J, Wei T, Zhao J, et al (2016). Multifunctional aptamer-based nanoparticles for targeted drug delivery to circumvent cancer resistance. Biomaterials, 91, 44-56. https://doi.org/10.1016/j.biomaterials.2016.03.013
  13. Lu R-M, Chen M-S, Chang D-K, et al (2013). Targeted drug delivery systems mediated by a novel peptide in breast cancer therapy and imaging. PLoS One, 8, e66128. https://doi.org/10.1371/journal.pone.0066128
  14. Muller RH, Alexiev U, Sinambela P, et al (2016). Nanostructured lipid carriers (NLC): The second generation of solid lipid nanoparticles. in 'percutaneous penetration enhancers chemical methods in penetration enhancement', Eds Springer, 161-85.
  15. Nair HB, Huffman S, Veerapaneni P, et al (2011). Hyaluronic acid-bound letrozole nanoparticles restore sensitivity to letrozole-resistant xenograft tumors in mice. J Nanosci Nanotechnol, 11, 3789-99. https://doi.org/10.1166/jnn.2011.3871
  16. Osborne CK, Schiff R (2011). Mechanisms of endocrine resistance in breast cancer. Annu Rev Med, 62, 233. https://doi.org/10.1146/annurev-med-070909-182917
  17. Patel K, Solanki N, Solanki S (2015). Nanostructured lipid carrier-a novel drug delivery. J Pharm Sci Bioscientific Res, 5, 385-92.
  18. Prabhakar U, Maeda H, Jain RK, et al (2013). Challenges and key considerations of the enhanced permeability and retention effect for nanomedicine drug delivery in oncology. Cancer Res, 73, 2412-7. https://doi.org/10.1158/0008-5472.CAN-12-4561
  19. Rasaie S, Ghanbarzadeh S, Mohammadi M, et al (2014). Nano phytosomes of quercetin: A promising formulation for fortification of food products with antioxidants. J Pharm Sci, 20, 96.
  20. Sabzichi M, Samadi N, Mohammadian J, et al (2016). Sustained release of melatonin: A novel approach in elevating efficacy of tamoxifen in breast cancer treatment. Coll Surf B, 145, 64-71. https://doi.org/10.1016/j.colsurfb.2016.04.042
  21. Selvamuthukumar S, Velmurugan R (2012). Nanostructured lipid carriers: a potential drug carrier for cancer chemotherapy. Lipids Health Dise, 11, 1. https://doi.org/10.1186/1476-511X-11-1
  22. Shao Z, Shao J, Tan B, et al (2015). Targeted lung cancer therapy: preparation and optimization of transferrin-decorated nanostructured lipid carriers as novel nanomedicine for codelivery of anticancer drugs and DNA. Int J Nanomedicine, 10, 1223. https://doi.org/10.2217/nnm.14.202
  23. Siddiqa AJ, Chaudhury K, Adhikari B (2014). Letrozole dispersed on poly (vinyl alcohol) anchored maleic anhydride grafted low density polyethylene: A controlled drug delivery system for treatment of breast cancer. Coll Surf B, 116, 169-75. https://doi.org/10.1016/j.colsurfb.2013.12.040
  24. Tupal A, Sabzichi M, Ramezani F, et al (2016). Dermal delivery of doxorubicin-loaded solid lipid nanoparticles for the treatment of skin cancer. J Microencapsul, 33, 372-80. https://doi.org/10.1080/02652048.2016.1200150
  25. Wicaksono P, Martien R, Ismail H (2015). Formulation and cytotoxicity of ribosome-inactivating protein mirabilis jalapa L. nanoparticles using alginate-low viscosity chitosan conjugated with anti-epcam antibodies in the T47D breast cancer cell line. Asian Pac J Cancer Prev, 17, 2277-84.